20260901-招银国际-映恩生物-B-09606.HK-Eyes_on_the_upcoming_ADC_+_IO2.0_data_readouts_5页_1mb

DualityBio (9606 HK) Summary

Core Content and Strategy

DualityBio is focusing on its ADC + IO2.0 strategy in collaboration with BioNTech, aiming to combine its antibody-drug conjugate (ADC) assets with pumitamig, a bispecific antibody targeting PD-L1×VEGF. The company's core value driver is Elfe-D, a B7-H3 ADC, which has shown promising results in metastatic castration-resistant prostate cancer (mCRPC). The upcoming data readouts at WCLC 2026 and ESMO 2026 are expected to be significant catalysts for the company's valuation and market sentiment.

Key Assets and Clinical Progress

• Elfe-D (DB-1311/BNT324):

  • Demonstrates compelling durability in heavily pretreated patients (median rPFS 11.3 months; median OS 22.5 months).
  • Shows encouraging activity even in post-Lu-177 settings.
  • Has a highly tolerable safety profile (only 20% Gr≥3 TRAEs).
  • Advanced into a global Phase 3 study versus docetaxel in taxane-naïve mCRPC, which is a key de-risking step.
  • Expected to have blockbuster potential in the mCRPC market, already validated by Pluvicto's commercial success.

• DB-1303/BNT323 (T-pam; HER2 ADC) and DB-1305/BNT325 (TROP2 ADC):

  • Being evaluated in combination with pumitamig across four global studies.
  • T-pam is expected to report global Phase 3 data in HR+/HER2-low breast cancer in 4Q26.

Upcoming Data Readouts

• WCLC 2026:

  • Expected LBA presentation for Elfe-D + pumitamig in lung cancer.
  • Includes safety data in NSCLC and SCLC, along with initial efficacy observations in SCLC.
  • NSCLC efficacy is still immature due to ongoing expansion enrollment.

• ESMO 2026:

  • Additional Phase 2 combination data for Elfe-D in advanced solid tumors (OC, CC, HCC, HNSCC).
  • Initial T-pam + pumitamig data in HR+/HER2-low/ultra-low breast cancer.

Financial Overview

• Revenue:

  • FY24A: RMB1,941 million
  • FY25A: RMB1,852 million
  • FY26E: RMB1,046 million
  • FY27E: RMB1,202 million
  • FY28E: RMB1,728 million
  • YoY growth in 1H26: -43.5%

• Net Profit:

  • FY24A: RMB-1,050 million
  • FY25A: RMB-2,595 million
  • FY26E: RMB-1,086 million
  • FY27E: RMB-1,242 million
  • FY28E: RMB-1,191 million

• R&D Expenses:

  • Rose 74% YoY to RMB607 million in 1H26.
  • Expected to increase further in subsequent years.

• Cash Balances:

  • Remained solid at RMB3.0bn as of 1H26.
  • A-share financing is on track.

• Collaboration with Genentech:

  • Announced US$45mn upfront and potential milestone payments of over US$1bn, validating the DUPAC platform value.

Valuation and Target Price

• DCF Valuation:

  • Equity value: RMB22,320 million (HK$25,953 million).
  • Target Price (TP) revised to HK$284.50 (from previous HK$383.47).
  • Up/Downside: 58.1%.
  • Current Price: HK$180.00.

• Key Assumptions:

  • Terminal growth rate: 3.5%
  • WACC: 9.87%
  • Cost of equity: 13.0%
  • Cost of debt: 3.0%

Share Performance

• 1-month: -1.0%
• 3-months: -12.0%
• 6-months: -42.9%
• Relative performance: -11.8% over 3 months

Shareholding Structure

• LAV Fund: 8.7%
• Shanghai Yingjia: 7.0%
• Source: Bloomberg

Market Capitalization and Liquidity

• Market Cap (HK$): HK$16,420.4 million
• Avg 3 mths t/o (HK$): HK$233.6 million
• 52w High/Low (HK$): 510.00 / 162.80
• Total Issued Shares (mn): 91.2

Risks

• Rising competition in B7-H3 ADCs.
• Uncertainty regarding the clinical data of ADC + IO2.0 combinations.

Analyst Ratings

• BUY: Stock with potential return of over 15% over the next 12 months.
• HOLD: Stock with potential return of +15% to -10% over the next 12 months.
• SELL: Stock with potential loss of over 10% over the next 12 months.

CMBIGM Ratings

• BUY: Recommended for those seeking a potential return of over 15% over the next 12 months.

Analyst Certification

• The analyst certifies that the views expressed in the report accurately reflect personal views.
• No part of the analyst’s compensation is directly or indirectly related to the specific views in the report.

Important Disclosures

• The report is not an offer or solicitation to buy or sell securities.
• CMBIGM is not a registered broker-dealer in the U.S.
• The report is intended solely for major US institutional investors.
• The information is based on public data and not guaranteed for accuracy or completeness.
• Investors are advised to consult professional financial advisors for independent evaluation.

Conclusion

DualityBio is positioned as a promising player in the ADC and IO2.0 space, with a strong focus on mCRPC and lung cancer. The upcoming data from WCLC and ESMO could significantly impact the company's valuation and market perception. Despite financial losses in recent years, the company has solid cash reserves and a strategic collaboration with Genentech that may drive future growth. The BUY rating is maintained, reflecting the potential for significant returns over the next year.